Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 13680. Отображено 100.
05-01-2012 дата публикации

Pharmaceutical Composition Comprising Aliskiren

Номер: US20120003308A1
Принадлежит: Individual

The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. It provides compressed bilayer tablets with both a high drug load and suitable physical properties, which can be produced using conventional equipment.

Подробнее
05-01-2012 дата публикации

Solid Dosage Forms Of Bendamustine

Номер: US20120003309A1
Принадлежит: ASTELLAS DEUTSCHLAND GMBH

In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.

Подробнее
05-01-2012 дата публикации

Dpp iv inhibitor formulations

Номер: US20120003313A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Подробнее
12-01-2012 дата публикации

Nucleotide Analogue Prodrug and the Preparation Thereof

Номер: US20120010171A1
Автор: Jiandong Yuan

The present invention provides: 1) Derivative solid form of 9-[2-(R)-[bis[pivaloyloxymethoxy]-phosphinylmethoxy]propyl]adenine (bis-POM PMPA, abbreviated as TD hereinafter), including crystalline form A and form B of TD, TD fumarate salts and cyclodextrin inclusion complex of TD; 2) Synthesis and purification methods of TD and Solidification method of TD oil, including converting TD oil to crystalline TD in Form A and Form B, solid TD salts and cyclodextrin inclusion complex of TD; 3) Stable pharmaceutical compositions containing TD derivatives and their preparation; 4) The use of the above TD derivatives in the antiviral treatments, especially in the treatment of HIV, HBV, CMV, HSV-1, HSV-2 and human Herpes virus infections.

Подробнее
22-03-2012 дата публикации

Method and Formulation for Treating Resistance to Antihypertensives and Related Conditions

Номер: US20120070501A1
Автор: Moshe Laudon, Nava Zisapel
Принадлежит: Neurim Pharmaceuticals 1991 Ltd

A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient.

Подробнее
12-04-2012 дата публикации

Extended release opioid abuse deterrent compositions and methods of making same

Номер: US20120087982A1
Принадлежит: Acura Pharmaceuticals Inc

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Подробнее
03-05-2012 дата публикации

Pharmaceutical formulation containing gelling agent

Номер: US20120108622A1
Принадлежит: Purdue Pharma LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
17-05-2012 дата публикации

Method for on-demand contraception

Номер: US20120122828A1
Автор: André Ulmann, Erin Gainer
Принадлежит: Laboratoire HRA Pharma SAS

The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.

Подробнее
05-07-2012 дата публикации

method for producing a nutraceutical composition and the nutraceutical produced by the method

Номер: US20120171186A1
Автор: Woon San Liang
Принадлежит: Individual

A method for producing a nutraceutical composition comprising a combination of oil soluble antioxidants derived from an edible oil and water soluble antioxidants derived from a plant extract, wherein the plant extract further provides a natural surfactant; and the nutraceutical composition produced by that method.

Подробнее
12-07-2012 дата публикации

Co-Processed Excipient Compositions

Номер: US20120178822A1
Принадлежит: ISP Investments LLC

An oral solid dosage form having improved dissolution profile and a method of producing the same are provided. The present invention particularly provides a co-processed excipient composition and a method of producing the same. More particularly, it relates to a co-processed binary mixture of crosslinked polyvinylpyrrolidone and calcium silicate; wherein the weight ratio of crosslinked polyvinylpyrrolidone and calcium silicate is in the range of 1:1 to 20:1. The binary mixture when combined with a poorly soluble drug enhances its dissolution and extent of release.

Подробнее
02-08-2012 дата публикации

Deferacirox dispersible tablets

Номер: US20120196909A1
Принадлежит: NOVARTIS AG

The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.

Подробнее
18-10-2012 дата публикации

Compositions for the treatment of cns-related conditions

Номер: US20120264782A1
Принадлежит: Adamas Pharmaceuticals Inc

The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Подробнее
15-11-2012 дата публикации

Methods for the Treatment of CNS-Related Conditions

Номер: US20120288560A1
Принадлежит: Adamas Pharmaceuticals Inc

The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.

Подробнее
15-11-2012 дата публикации

Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same

Номер: US20120289550A1
Автор: Jeffrey O. Phillips
Принадлежит: University of Missouri System

The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided

Подробнее
29-11-2012 дата публикации

Composition comprising solanum glaucophyllum for preventing and/or treating hypocalcaemia and for stabilizing blood calcium levels

Номер: US20120301513A1
Принадлежит: HERBONIS AG

The present invention provides a pharmaceutical and/or veterinary composition comprising a retard release formulation of a Solarium glaucophyllum preparation. The composition further preferably comprises a calcium source. The composition of the invention is suitable to prevent and/or treat hypocalcaemia. Furthermore, the composition is suitable to prevent milk fever in cows. Advantageously, the composition is administered only once before calving so as to prevent the occurrence of milk fever in cows.

Подробнее
29-11-2012 дата публикации

Directly compressible magnesium hydroxide carbonate

Номер: US20120301520A1
Принадлежит: Merck Patent GmBH

The present invention relates to a directly compressible magnesium hydroxide carbonate and to a process for the preparation thereof, and to the use thereof.

Подробнее
06-12-2012 дата публикации

Oral medication for the treatment of hemorrhoids and method of use

Номер: US20120308553A1
Автор: Joseph P. Thornton
Принадлежит: Individual

A natural supplement in the form of an orally ingested tablet for treatment of hemorrhoids. Bromelain and Psyllium (e.g., Psyllium husk powder) are the primary active ingredients in the natural supplement tablet. Optionally, Witch Hazel, in the form of Witch Hazel leaf, for example, may be added to the composition. Secondary ingredients include Dicalcium Phosphate, Cellulose, Croscarmellose Sodium, Stearic Acid and Silicon Dioxide. Based on case studies the natural supplement outperforms over-the-counter and prescribed hemorrhoid medications.

Подробнее
06-12-2012 дата публикации

Oral form of administration comprising entecavir

Номер: US20120308652A1
Автор: Daniela Stumm, Jana Paetz
Принадлежит: Individual

The invention relates to pharmaceutical formulations, preferably in the form of an oral dosage form, for the treatment of chronic hepatitis-B virus infections, containing micronised Entecavir, and processes for preparing it. The invention further relates to intermediates containing micronised entecavir, in which the D50 value for the particle size distribution is less than 50 μm, and processes for preparing them.

Подробнее
10-01-2013 дата публикации

Modified release formulations of memantine oral dosage forms

Номер: US20130012593A1
Принадлежит: Forest Laboratories Holdings Ltd

The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions, following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

Подробнее
31-01-2013 дата публикации

Melatonin tablet and methods of preparation and use

Номер: US20130028943A1
Автор: John A. McCarty
Принадлежит: Individual

The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.

Подробнее
31-01-2013 дата публикации

Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan

Номер: US20130028974A1
Принадлежит: HANMI SCIENCE CO LTD

Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia.

Подробнее
28-02-2013 дата публикации

Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

Номер: US20130052231A1
Принадлежит: JOHNS HOPKINS UNIVERSITY

The present invention relates to the field of organ transplantation. In one aspect, the present invention provides methods of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.

Подробнее
28-02-2013 дата публикации

Formulations for oral delivery of adsorbents in the gut

Номер: US20130052269A1
Принадлежит: Da Volterra SAS

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

Подробнее
04-04-2013 дата публикации

Baclofen and acamprosate based therapy of neurological disorders

Номер: US20130085122A1
Принадлежит: Pharnext SA

The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.

Подробнее
18-04-2013 дата публикации

Controlled release drug delivery compostion

Номер: US20130095176A1
Автор: Amina Odidi, Isa Odidi
Принадлежит: INTELLIPHARMACEUTICS CORP

A controlled release delivery composition comprising: a housing adapted for oral administration; and a plurality of discrete vehicles assembled within the housing, each of the vehicles are not compressed together, each of the vehicles being a bead, a pellet, a tablet, and/or granules compressed into a preselect shape, wherein each of the vehicles comprise a different combination and/or amount of an active agent, an amino acid, a buffer, and a polymer, such that each of the vehicles comprises a different active agent and/or release property from each other, wherein each of the vehicles releases the active agent independently of each other, and wherein each of the vehicles remains independent from each other and intact within the housing prior to oral administration of the delivery composition.

Подробнее
18-04-2013 дата публикации

Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof

Номер: US20130095181A1
Принадлежит: Vertex Pharmaceuticals Inc

A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Подробнее
25-04-2013 дата публикации

Method and agent for detecting drugs in beverages

Номер: US20130098286A1
Принадлежит: Ethypharm SAS

The present invention relates to a method for combating chemical submission, which comprises: putting into solution, in a beverage, a pharmaceutical form comprising an active ingredient and at least 0.05 mg, preferably from 0.2 to 5 mg, even more preferentially from 0.3 to 2 mg of at least one water-soluble colouring agent chosen from: indigocarmine or E 132, erythrosine or E 127, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarine green SS, orange II, tartrazine and Sunset yellow FCF, detecting the pharmaceutical form, said detection being characterized by the immediate change in colour of the beverage; it also relates to the use of said colorant for combating chemical submission, and also to a non-film-coated solid pharmaceutical form comprising said colorant.

Подробнее
02-05-2013 дата публикации

Methods and compositions for treating hepatitis c virus

Номер: US20130109647A1
Принадлежит: GILEAD PHARMASSET LLC

Disclosed herein is a method of treating a subject infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. Also disclosed herein is a composition useful for the treatment of hepatitis C virus infection, said composition comprising an effective amount of GS-7977 and an effective amount of ribavirin.

Подробнее
09-05-2013 дата публикации

Gastric retentive gabapentin dosage forms and methods for using same

Номер: US20130116320A1
Принадлежит: Depomed Inc

Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen.

Подробнее
23-05-2013 дата публикации

DIVERSION-RESISTANT MICROGRANULES AND MICROTABLETS

Номер: US20130129825A1
Автор: Billoet Vincent
Принадлежит: ETHYPHARM

The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered. 1. Oral dosage form based on microgranules and/or microtablets comprising two populations of microgranules or microtablets , the first population comprising at least one active principle that could create a dependency and a gelling agent , and the second population , without active principle and gelling agent , comprising at least one gelling activator.2. The dosage form according to claim 1 , constituted of microgranules or microtablets.3. The dosage form according to claim 2 , further comprising a first population of microgranules comprising a neutral support and at feast one mounting layer comprising at least one active principle and optionally a pharmaceutically acceptable binder agent and a gelling agent present either in the mounting layer or in a separate layer claim 2 , and a second population of microgranules comprising a neutral support and at least one mounting layer comprising at least one gelling activator.4. The dosage form according to claim 1 , wherein the gelling agents are chosen from polyacrylic acids and derivatives thereof claim 1 , polyoxyethylenes claim 1 , polyvinyl alcohols claim 1 , polyvinylpyrrolidones (PVP) claim 1 , gelatines ...

Подробнее
06-06-2013 дата публикации

Sublingual zolpidem formulations

Номер: US20130143912A1

The present disclosure provides pharmaceutical compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the compositions devoid of buffer and in the presence of alkaline oxides capable of raising the pH of saliva to a pH greater than about 7.0 thereby facilitate the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.

Подробнее
27-06-2013 дата публикации

Small-volume oral transmucosal dosage forms

Номер: US20130165481A1
Принадлежит: AcelRx Pharmaceuticals Inc

Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.

Подробнее
27-06-2013 дата публикации

Composition and Method for Treating Neurological Disease

Номер: US20130165517A1
Принадлежит: Adamas Pharmaceuticals Inc

A method of treating a patient with Parkinson's disease is provided. The method comprises orally administering to the patient a first agent comprising levodopa and once-daily, orally administering to the patient a second agent comprising amantadine, or a pharmaceutically acceptable salt thereof. The amount of levodopa administered is reduced by 20% to 80% of the amount required in the absence of amantadine.

Подробнее
04-07-2013 дата публикации

FAST DISSOLVING PHARMACEUTICAL COMPOSITION COMPRISING LORNOXICAM

Номер: US20130171254A1
Принадлежит: Abbott Healthcare Private Limited

The present invention discloses a fast dissolving pharmaceutical composition comprising lornoxicam or pharmaceutically acceptable salts thereof as an active ingredient along with at least one alkalinizer, at least one organic acid and at least one pharmaceutically acceptable excipient. The present invention also discloses processes of preparing fast dissolving pharmaceutical composition. 1. A fast dissolving pharmaceutical composition comprising:a. lornoxicam or pharmaceutically acceptable salts thereof;b. at least one alkalinizer;c. at least one organic acid; andd. pharmaceutically acceptable excipients,wherein the weight ratio of lornoxicam to alkalinizer(s) is in the range of from about 1:43 to about 1:85 and the weight ratio of alkalinizer(s) to organic acid(s) is in the range of from about 3:1 to about 100:1,wherein at least 30% of lornoxicam is released from said composition within 3 minutes and at least 40% of lornoxicam is released from said composition within 10 minutes.2. The composition as claimed in claim 1 , wherein said composition exhibits a lornoxicam plasma Tof less than 45 minutes.3. The composition as claimed in claim 1 , wherein said composition exhibits a lornoxicam plasma Cof more than 950 ng/ml after the administration of a 8 mg dose of lornoxicam.4. The composition as claimed in claim 1 , wherein said composition exhibits a lornoxicam AUCof about 10 ng.h/ml to about 70 ng.h/ml after the administration of a 8 mg dose of lornoxicam.5. The composition as claimed in claim 1 , wherein said composition exhibits a lornoxicam AUCof about 70 ng.h/ml to about 200 ng.h/ml. after the administration of a 8 mg dose of lornoxicam6. The composition as claimed in claim 1 , wherein said composition exhibits a lornoxicam AUCof about 200 ng.h/ml to about 500 ng.h/ml after the administration of a 8 mg dose of lornoxicam.7. The composition as claimed in claim 1 , wherein the amount of lornoxicam or pharmaceutically acceptable salts thereof is in the range of about ...

Подробнее
04-07-2013 дата публикации

Extended release opioid abuse deterrent compositions and methods of making same

Номер: US20130171257A1
Принадлежит: Acura Pharmaceuticals Inc

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Подробнее
18-07-2013 дата публикации

Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same

Номер: US20130183382A1
Принадлежит: SANOFI SA

The present invention relates to fexofenadine granules, to a composition containing them and to a process for the hot-melt coating of fexofenadine. The process for the hot-melt coating of fexofenadine allows efficient masking of its bitter taste without, however, unacceptably slowing down its dissolution.

Подробнее
01-08-2013 дата публикации

Abuse-proofed dosage form

Номер: US20130195935A1
Принадлежит: GRUENENTHAL GmbH

A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.

Подробнее
01-08-2013 дата публикации

1',3'-disubstituted-4-pheny-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones

Номер: US20130196992A1

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

Подробнее
08-08-2013 дата публикации

Pharmaceutical composition for the prolonged release of trimetazidine

Номер: US20130202710A1
Принадлежит: Laboratoires Servier SAS

Composition for the prolonged release of trimetazidine wherein the inner phase comprises trimetazidine and the outer layer comprises a retardant and an anti-agglomerant.

Подробнее
15-08-2013 дата публикации

Compositions and methods for treating sleep disorders

Номер: US20130210856A1
Принадлежит: Individual

The present invention provides liquid dosage forms for treating narcolepsy. The liquid dosage form includes zolpidem or a pharmaceutically acceptable salt thereof, a carbonate salt, a metal oxide, and a borate salt. The present invention also provides methods for treating somnambulism. The methods include administering an emulsion that includes zolpidem, a bicarbonate salt, a citrate salt, and a phosphate salt.

Подробнее
19-09-2013 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20130245055A1

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
24-10-2013 дата публикации

PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INTENDED TO PREVENT MISUSE

Номер: US20130280326A1
Принадлежит:

The present invention is directed to oral pharmaceutical forms, the composition of which makes it possible to prevent possible misuse of the active principle present therein. The present invention thus relates to a pharmaceutical composition for oral administration intended to prevent abuse of use at the expense of a third party. 1. A pharmaceutical composition for oral administration , comprising an active principle which might form the object of an abuse of use , or one of its pharmaceutically acceptable salts , and further comprising components which , if the composition is introduced into an aqueous drink , which optionally comprises alcohol , generate visual means corresponding to an opacification of the drink and to at least one other visual means chosen from effervescence , the formation of insoluble particles , the flotation of the tablet when the composition is in the form of a tablet , and combinations of these visual means , wherein the components generating the said opacification of the drink comprise titanium dioxide particles.2. The pharmaceutical composition according to claim 1 , wherein the components generating the opacification of the drink consist of titanium dioxide particles.3. The pharmaceutical composition according to claim 1 , comprising at least 15 mg of titanium dioxide particles.4. The pharmaceutical composition according to claim 3 , comprising at least 20 mg of titanium dioxide particles.5. The pharmaceutical composition according to claim 1 , comprising at least one effervescence generator.6. The pharmaceutical composition according to claim 5 , wherein the effervescence generator is a carbon dioxide generator claim 5 , chosen from a carbonate or a bicarbonate of an alkali metal claim 5 , of an alkaline earth metal or of an amino acid; calcium carbonate; sodium bicarbonate; potassium bicarbonate; potassium carbonate; L-lysine carbonate; arginine carbonate; sodium sesquicarbonate; and mixtures thereof.7. The pharmaceutical composition ...

Подробнее
24-10-2013 дата публикации

ZOLPIDEM-BASED ORODISPERSIBLE PHARMACEUTICAL TABLET

Номер: US20130280327A1
Принадлежит:

The present invention is directed to oral pharmaceutical forms for rapid disintegration which make it possible to prevent possible misuse of the zolpidem present therein. The present invention thus relates to a zolpidem-based orodispersible tablet formulation intended to prevent abuse of use of the tablet at the expense of a third party. 1. An orodispersible pharmaceutical tablet , comprising zolpidem or one of its pharmaceutically acceptable salts; at least one disintegrating agent; at least one soluble agent of polyol type; and components which , if the tablet is introduced into an aqueous drink , which optionally comprises alcohol , generate visual means corresponding to an opacification of the drink and to at least one other visual means chosen from effervescence , the formation of insoluble particles , the flotation of the tablet , and combinations of these visual means , wherein the components generating the opacification of the drink comprise titanium dioxide particles.2. The tablet according to claim 1 , wherein the components generating the opacification of the drink consist of titanium dioxide particles.3. The tablet according to claim 1 , comprising at least 15 mg of titanium dioxide particles.4. The tablet according to claim 1 , comprising at least one effervescence generator claim 1 , wherein the effervescence generator is a carbon dioxide generator chosen from a carbonate or a bicarbonate of an alkali metal claim 1 , of an alkaline earth metal or of an amino acid; calcium carbonate; sodium bicarbonate; potassium bicarbonate; potassium carbonate; L-lysine carbonate; arginine carbonate; sodium sesquicarbonate; and mixtures thereof.5. The tablet according to claim 4 , wherein the carbon dioxide generator is calcium carbonate.6. The tablet according to any claim 1 , additionally comprising a lipophilic excipient chosen from glyceryl stearates claim 1 , palmitate/stearates and behenates; hydrogenated vegetable oils and their derivatives; vegetable and ...

Подробнее
31-10-2013 дата публикации

Bromocriptine Formulations

Номер: US20130287848A1
Принадлежит: VEROSCIENCE LLC

The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.

Подробнее
14-11-2013 дата публикации

Effervescent compositions containing n-acetylcysteine

Номер: US20130302259A1
Принадлежит: ALPEX PHARMA SA

Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.

Подробнее
14-11-2013 дата публикации

Compositions Comprising Zoledronic Acid or Related Compounds for Relieving Inflammatory Pain and Related Conditions

Номер: US20130303487A1
Автор: Herriot Tabuteau
Принадлежит: Antecip Bioventures II LLC

Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. Although an oral dosage form with enhanced bioavailability with respect to the bisphosphonate compound can be used, the treatment can also be effective using an oral dosage form that includes a bisphosphonate compound, such as zoledronic acid, wherein the bioavailability of the bisphosphonate is unenhanced, or is substantially unenhanced.

Подробнее
28-11-2013 дата публикации

Direct compression polymer tablet core

Номер: US20130315995A1
Принадлежит: Genzyme Corp

The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 80% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.

Подробнее
12-12-2013 дата публикации

Oral formulations and lipophilic salts of methylnaltrexone

Номер: US20130330407A1
Принадлежит: WYETH LLC

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

Подробнее
19-12-2013 дата публикации

Pharmaceutical compositions of maraviroc and process for the preparation thereof

Номер: US20130337063A1
Принадлежит: HETERO RESEARCH FOUNDATION

The present disclosure relates to solid dosage forms comprising the CCR5 co-receptor antagonist maraviroc. More particularly, the present disclosure relates to a solid oral dosage form containing maraviroc which has favorable disintegration properties.

Подробнее
09-01-2014 дата публикации

Tamper Resistant Solid Oral Dosage Forms

Номер: US20140010874A1
Автор: SACKLER Richard S.
Принадлежит: Purdue Pharma L.P.

Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent. 1. A solid oral dosage form comprising:(a) an inert tamper resistant core; and(b) a coating surrounding the core, the coating comprising active agent.2. The solid oral dosage form of claim 1 , wherein the tamper resistant core is resistant to splitting claim 1 , crushing claim 1 , shearing claim 1 , grinding claim 1 , chewing or a combination thereof.3. The solid oral dosage form of claim 2 , wherein the tamper resistant core is resistant to splitting.4. The solid oral dosage form of claim 2 , wherein the tamper resistant core is resistant to crushing.5. The solid oral dosage form claim 1 , wherein the tamper resistant core has a breaking strength of at least 400 Newtons.6. The solid oral dosage form claim 1 , wherein the tamper resistant core comprises a metal oxide claim 1 , a carbide claim 1 , a nitride or a combination thereof.7. The solid oral dosage form claim 1 , wherein the inert tamper resistant core comprises an inner component and an outer component surrounding the inner component.8. The solid oral dosage form of claim 7 , wherein the inner component is tamper resistant claim 7 , the outer component is tamper resistant or both the inner and outer components are tamper resistant.9. The solid oral dosage form of claim 8 , wherein the outer component is tamper resistant.10. The solid oral dosage form of any one of claims claim 1 , wherein the coating provides an immediate release of the active agent.11. The solid oral dosage form claim 1 , wherein the coating provides a controlled release of the active agent.12. The solid oral dosage form claim 1 , wherein the coating further comprises a pharmaceutically acceptable excipient.13. The solid oral dosage form of claim 12 , wherein the excipient is an immediate release excipient.14. The solid oral dosage form of claim 13 , ...

Подробнее
09-01-2014 дата публикации

Composition and method for treatment of diabetes

Номер: US20140011876A1
Принадлежит: Biokier Inc

The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of long chain fatty acid to the colon by bypassing the upper digestive tract.

Подробнее
16-01-2014 дата публикации

Tableting Aid

Номер: US20140017390A1
Принадлежит:

The invention relates to a directly compressible tableting excipient for use in foodstuffs (dietary supplement), containing: 15-. (canceled)6. A directly compressible tableting excipient for use in foods , the directly compressible tableting excipient comprising:78-97% of a microcrystalline cellulose or a silicified microcrystalline cellulose;a lecithin or phosphatide or monoglyceride or diglyceride as an emulsifier;0.1-5% of a saturated vegetable fat as a lubricant;a colloidal silicon dioxide as a glidant;sodium carboxymethyl cellulose as a disintegrant.7. A method for producing the directly compressible tableting excipient of claim 6 , the method comprising:performing wet granulation including mixing granulation or perforated-disc granulation or fluidized-bed granulation or extrusion or Shugi granulation or spray drying. In the field of pharmaceutical technology, the tablet is the most common form of compressing active agents. Consequently, there is a wide knowledge in pharmacy and a lot of experience in the production of tablets. In addition, there is a wide range of inactive ingredients for the manufacture of tablets, granulates and other solid forms.The inactive ingredients for the production of medicinal products are defined and described in general in official dispensatories (pharmacopoeia). There are binding agents, mold release agents, lubricants, disintegrants, solubilizing agents, and many others.In addition to the medicinal products, so-called dietary supplements have become known in recent years. The dietary supplements are intended to offset deficits in essential nutrients that are not or not sufficiently provided to the human body under certain circumstances.Dietary supplements include vitamin and mineral preparations, preparations of amino acids, enzymes, trace elements and various plant extracts.Dietary supplements are subject in most countries to foodstuff legislation. Accordingly, the list of the permitted inactive ingredients for pressing tablets ...

Подробнее
30-01-2014 дата публикации

EFFERVESCENT FORMULATIONS COMPRISING DEXKETOPROFEN

Номер: US20140030326A1
Автор: Bilgic Mahmut
Принадлежит:

The present invention relates to water-soluble formulations comprising the active agent dexketoprofen and to a process for production of said formulations. The present invention also relates to pharmaceutical formulations comprising dexketoprofen which is used in symptomatic treatment of mild to moderate pains such as musculoskeletal pains, dysmenorrhoea, toothache, post-operative pains. The formulations are characterized in being in effervescent form. 1. A formulation comprising dexketoprofen , pharmaceutically acceptable solvates , hydrates , salts , amorphous , and/or crystalline forms thereof , characterized in that said formulation is in water-soluble form.2. (canceled)3. The formulation according to claim 1 , characterized in that dexketoprofen is in the form of trometamol salt.4. The formulation according to claim 1 , characterized in that said formulation is in the form of water-soluble powder claim 1 , water-soluble granule claim 1 , water-soluble tablet claim 1 , effervescent powder claim 1 , effervescent granule or effervescent tablet.5. The formulation according to claim 1 , characterized in that the amount of dexketoprofen is in the range of 1 mg to 250 mg or 5 mg to 100 mg.6. (canceled)7. The formulation according to claim 1 , characterized in that said formulation comprises dexketoprofen having d90 value in the range of 250-600 μm claim 1 , 300-500 μm claim 1 , or 350-450 μm.89-. (canceled)10. The formulation according to claim 1 , characterized in that;said formulations are in water soluble tablet or effervescent tablet form; andsaid formulations comprise dexketoprofen having d90 value in the range of 250-600 μm, 300-500 μm, or 350-450 μm.1112-. (canceled)13. The formulation according to claim 1 , wherein said formulation further comprises other pharmaceutically acceptable excipients along with dexketoprofen.14. The formulation according to claim 13 , wherein said formulation comprises excipients such as binder claim 13 , carrier claim 13 , sweetener ...

Подробнее
30-01-2014 дата публикации

Compositions and Methods for Treating Bruises

Номер: US20140031422A1
Принадлежит: M Alphabet LLC

A composition for the treatment of bruising is disclosed. The composition can include an antioxidant, one or more citrus flavanoids, as active agents along with a pharmaceutically acceptable excipient or filler. The compositions are nutriceutical formulations having the capacity to reduce the number of bruises that occur over time and that reduce the healing time of bruises. The compositions are preferably in tablet form for oral consumption one or more times per day. A method of reducing bruising is also disclosed in which a patient in need of a treatment for bruising or at risk of developing bruises is identified. The composition can then be administered orally to the patient.

Подробнее
27-02-2014 дата публикации

Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof

Номер: US20140056977A1
Принадлежит: Ipsen Pharma SAS

The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.

Подробнее
06-03-2014 дата публикации

MULTILAYER TABLET

Номер: US20140065217A1
Принадлежит: Intelgenx Corp.

A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active compound, and at least one release-modulating layer laminated to each side of the core layer. The dosage form can be prepared using simple, inexpensive tablet compression techniques. 1. A trilayer tablet , comprising:a porous, non-erodible core layer containing at least one pharmaceutically active compound and/or at least one nutritionally active compound; andat least one erodible layer laminated to each side of the non-erodible core layer;wherein the porous, non-erodible core layer comprises at least one insoluble polymer defining a matrix.2. The trilayer tablet of claim 1 , wherein the active compound is soluble in a gastrointestinal fluid.3. The trilayer tablet of claim 1 , wherein the active compound is selected from Tramadol HCl claim 1 , Bupropion and Propanolol.4. The trilayer tablet of claim 1 , in which the porous claim 1 , non-erodible core layer further comprises a pore-forming material.5. The trilayer tablet of claim 1 , in which at least one insoluble polymer in the porous non-erodible core layer is a swellable insoluble polymer.6. The trilayer tablet of claim 1 , wherein the layers laminated to each side of the core layer are comprised of at least one swellable erodible polymer.7. The trilayer tablet of claim 1 , wherein at least one of the erodible layers comprises at least one polymer that is permeable to water.8. The trilayer tablet of claim 1 , wherein at least one of the erodible layers comprises at least one insoluble polymer.9. The trilayer tablet of claim 1 , wherein at least one of the erodible layers comprises from about 10% to about 30% by weight of at least one insoluble polymer.10. The trilayer tablet of claim 1 , wherein at least one of the erodible layers comprises from about 15% to about 25% by weight of at least one insoluble polymer. This ...

Подробнее
06-03-2014 дата публикации

Modified release compositions comprising tacrolimus

Номер: US20140065225A1
Автор: Per Holm, Tomas Norling
Принадлежит: Veloxis Pharmaceuticals AS

A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Подробнее
13-03-2014 дата публикации

STABLE PHARMACEUTICAL COMPOSITION OF SAXAGLIPTIN

Номер: US20140072628A1
Принадлежит: Glenmark Generics Ltd.

Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer. 1. A stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof , wherein a seal coat is not present between the substrate and the saxagliptin layer.2. The stable pharmaceutical composition of claim 1 , wherein the layer of saxagliptin further contains one or more pharmaceutically acceptable additives.3. The stable pharmaceutical composition of claim 2 , wherein the one or more pharmaceutically acceptable additives are selected from the group consisting of polymers claim 2 , waxy substances claim 2 , and readily available coating dispersions.4. The stable pharmaceutical composition of claim 2 , wherein the one or more pharmaceutically acceptable additives are a polyvinyl alcohol or a hydroxypropylmethyl cellulose based coating dispersion.5. The stable pharmaceutical composition of claim 1 , wherein the substrate is a core tablet claim 1 , water soluble and water insoluble non pareil seeds claim 1 , mini tablets claim 1 , beads claim 1 , beadlet claim 1 , pellet or spheroids.6. The stable pharmaceutical composition of claim 1 , wherein the substrate is a core tablet.7. The stable pharmaceutical composition of claim 1 , wherein saxagliptin is incorporated as a monohydrate or amorphous claim 1 , and converts to the hydrochloride salt in the process of depositing over a substrate.8. The stable pharmaceutical composition of claim 7 , wherein saxagliptin hydrochloride is amorphous or crystalline.9. The stable pharmaceutical composition of claim 1 , wherein total cyclic amidine impurity doesn't exceed 0.15% at 3M 40° C./75% RH stability condition.10. A process for preparing a stable pharmaceutical ...

Подробнее
20-03-2014 дата публикации

Treatment of cerebral ischemia

Номер: US20140080873A1
Принадлежит: Pharnext SA

The present invention relates to new compositions and methods for protecting neuronal cells from ischemic or hypoxic events. More precisely, this invention provides new combinatorial therapies that efficiently protect neuronal cells from ischemia or hypoxia.

Подробнее
27-03-2014 дата публикации

Controlled Agglomeration

Номер: US20140086991A1
Принадлежит: Veloxis Pharmaceuticals AS

A process for the preparation of a particu 1265 late material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5 DEG C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.

Подробнее
03-04-2014 дата публикации

Method for Producing Orodispersible Tablets

Номер: US20140093567A1
Принадлежит: NIPRO CORPORATION

A method for easily producing orodispersible tablets that secure an eluting behavior of a principal agent in the digestive tract and mask unpleasant taste in the oral cavity is provided. Provided is a method for producing orodispersible tablets which includes mixing an additive to a principal agent to form principal agent particles as a granulation process, coating the principal agent particles with a coating agent to form coated particles as a coating process, and tableting the coated particles to form tablets as a tableting process, wherein the additive used in the granulation process contains a pH regulator, and the coating agent used in the coating process contains a pH-dependent polymer dissolving at pH 5 or more. 1. A method for producing orodispersible tablets which comprises:mixing an additive to a principal agent to form principal agent particles as a granulation process;coating the principal agent particles with a coating agent to form coated particles as a coating process; andforming the coated particles to form tablets as a tableting process;wherein the additive used in the granulation process comprises a pH regulator, andthe coating agent used in the coating process comprises a pH-dependent polymer dissolving at pH 5 or more.2. The method of claim 1 , wherein the principal agent is an acidic substance.3. The method of claim 1 , wherein the pH regulator is an acidic substance.4. An orodispersible tablet produced by the method of .5. The method of claim 2 , wherein the pH regulator is an acidic substance.6. An orodispersible tablet produced by the method of .7. An orodispersible tablet produced by the method of .8. An orodispersible tablet produced by the method of . The present invention relates to a method for producing orodispersible tablets.Since an orally disintegrating tablet is a dosage form that enables elderly people, children, and patients who have difficulty in swallowing to easily take the medicine and can be taken without water, it has ...

Подробнее
10-04-2014 дата публикации

Novel pharmaceutical composition

Номер: US20140099365A1

Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.

Подробнее
06-01-2022 дата публикации

ACTIVE INGREDIENT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHODS FOR THE PRODUCTION THEREOF

Номер: US20220000785A1
Принадлежит: Losan Pharma GmbH

The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate. 1. A non-effervescent solid medicinal form comprising:(i) 5 to 50% by weight of a moisture-sensitive active ingredient, wherein said moisture-sensitive active ingredient is not trimagnesium dicitrate; and(ii) 20-50% by weight of trimagnesium dicitrate acting as a drying agent that stabilizes the moisture-sensitive active ingredient against hydrolysis during storage;wherein said solid medicinal form comprises a tablet or granule, further wherein said solid medicinal form exhibits a relative equilibrium moisture, measured at 25° C., of at most 20%.2. The non-effervescent solid medicinal form of claim 1 , wherein said solid medicinal form further comprises 5 to 30% of weight of a microcrystalline cellulose.3. The non-effervescent solid medicinal form of claim 1 , wherein said solid medicinal form exhibits a relative equilibrium moisture claim 1 , measured at 25° C. claim 1 , of at most 15%.4. The non-effervescent solid medicinal form of claim 1 , wherein said solid medicinal form exhibits a drying loss claim 1 , measured at 120° C./30 min claim 1 , of at most 6%.5. The non-effervescent solid medicinal form of claim 1 , wherein said solid medicinal form is a tablet.6. The non-effervescent solid medicinal form of claim 5 , wherein said tablet comprises at least one further excipient selected from the group consisting of lactose claim 5 , mannitol claim 5 , xylitol claim 5 , lubricants claim 5 , disintegrants claim 5 , silica claim 5 , and combinations thereof.7. The non- ...

Подробнее
07-01-2016 дата публикации

METHOD OF TREATING VITAMIN B12 DEFICIENCY

Номер: US20160000716A1
Автор: McCarty John
Принадлежит:

The present invention relates generally to Vitamin B12 pharmaceutical composition and method of using the same for the treatment of Vitamin B12 deficiency and the various disorders that are related to such deficiency. In particular embodiments, the present invention is directed towards treatment methods comprising sublingual or buccal administration of a Vitamin B12 composition useful in the practice of such treatment. The present invention features compositions that include one or more Vitamin B 12 compounds, propylene glycol, a solid adsorbent and a solid water-soluble excipient, wherein the Vitamin B 12 compounds are in a propylene glycol solution. 1. A pharmaceutical composition containing a cobalamin in a solid dosage form for buccal or sublingual delivery , comprising:a cobalamin;propylene glycol into which the cobalamin is solvated; anda solid adsorbent to which the solvated cobalamin is adsorbed,the cobalamin being in solution in the solid dosage form of the pharmaceutical composition.2. The pharmaceutical composition of claim 1 , further comprising a co-solvent.3. The pharmaceutical composition of claim 1 , further comprising a water soluble excipient claim 1 , a distintegrant claim 1 , a lubricant claim 1 , or a mixture thereof.4. The pharmaceutical composition of claim 2 , further comprising a water soluble excipient claim 2 , a distintegrant claim 2 , a lubricant claim 2 , or a mixture thereof.5. The pharmaceutical composition of claim 1 , wherein the cobalamin comprises vitamin B12 claim 1 , cyanocobalamin claim 1 , hydroxocobalamin claim 1 , methylcobalamin claim 1 , or 5-deoxyadenosyl-cobalamin.6. The pharmaceutical composition of claim 2 , wherein the cobalamin comprises vitamin B12 claim 2 , cyanocobalamin claim 2 , hydroxocobalamin claim 2 , methylcobalamin claim 2 , or 5-deoxyadenosyl-cobalamin.7. The pharmaceutical composition of claim 3 , wherein the cobalamin comprises vitamin B12 claim 3 , cyanocobalamin claim 3 , hydroxocobalamin claim 3 , ...

Подробнее
07-01-2021 дата публикации

PHARMACEUTICAL COMPOSITION COMPRISING META ARSENITE AND METHOD OF MANUFACTURE

Номер: US20210000746A1
Автор: YANG Yong-jin
Принадлежит:

The present application relates to pharmaceutical compositions comprising a salt of arsenous acid, such as sodium meta arsenite or potassium meta arsenite, and methods of manufacturing the pharmaceutical compositions. 1. A pharmaceutical composition suitable for oral administration comprising: (i) a filler or diluent in a range of from about 5 to 95% w/w,', '(ii) a disintegrant in a range of from about 10 to 90% w/w,', '(iii) a glidant in a range of from about 0.1 to 5% w/w,', '(iv) a lubricant in a range of from about 0.1 to 5% w/w, and', '(v) optionally a binder in a range of from 0 to about 30% w/w; and, '(a) a solid core comprising sodium meta-arsenite or potassium meta-arsenite, and the following pharmaceutically acceptable excipients(b) an enteric coating comprising an enteric polymer;wherein the pharmaceutically acceptable excipients are selected such that oxidation of meta-arsenite to meta-arsenate is minimised,wherein the weight percentage of the enteric coating is from about 6% w/w to about 20% w/w with respect to the total weight of the pharmaceutical composition, andwherein the coating thickness is from about 6.5% to about 15% of the thickness of the pharmaceutical composition.2. The pharmaceutical composition according to claim 1 , wherein the amount of sodium meta-arsenite or potassium meta-arsenite in the solid core is about 0.1 to 5.0% w/w of the solid core.3. The pharmaceutical composition according to claim 1 , wherein the solid core comprises sodium meta-arsenite.4. The pharmaceutical composition according to claim 1 , wherein the filler or diluent is present in the solid core of the pharmaceutical composition in an amount of from about 10 to 90% w/w of the solid core.5. The pharmaceutical composition according to claim 1 , wherein the filler or diluent is selected from dibasic calcium phosphate anhydrous claim 1 , partially pregelatinised starch claim 1 , silicified microcrystalline cellulose claim 1 , microcrystalline cellulose claim 1 , calcium ...

Подробнее
03-01-2019 дата публикации

COMPRESSION-MOLDED PREPARATION

Номер: US20190000765A1
Принадлежит: NIPPON SHINYAKU CO., LTD.

An object of the present invention is to provide a compression-molded preparation which has an excellent disintegration property and can be easily produced despite the use of granules coated with a polymer coating film having a function such as masking of an unpleasant taste. A compression-molded preparation achieving the above object is characterized by including granules obtained by coating a polymer-coated, granulated substance, in which a granulated substance containing a drug is coated with a polymer coating film, with one kind or two or more kinds of additives selected from the group consisting of a metal stearate, stearic acid, a sucrose fatty acid ester, talc, and silicic acid. 1. A compression-molded preparation , comprising granules obtained by coating a polymer-coated , granulated substance , in which a granulated substance containing a drug is coated with a polymer coating film , with one kind or two or more kinds of additives selected from the group consisting of a metal stearate , stearic acid , a sucrose fatty acid ester , talc , and silicic acid.2. The compression-molded preparation according to claim 1 , wherein the additive is magnesium stearate claim 1 , calcium stearate claim 1 , a sucrose fatty acid ester claim 1 , or talc.3. The compression-molded preparation according to claim 1 , wherein the drug is a drug having an unpleasant taste.4. The compression-molded preparation according to claim 3 , wherein the drug having an unpleasant taste is one kind or two or more kinds selected from the group consisting of loxoprofen sodium claim 3 , ibuprofen sodium claim 3 , diclofenac potassium claim 3 , diclofenac sodium claim 3 , and naproxen sodium claim 3 , or hydrates thereof.5. The compression-molded preparation according to claim 1 , wherein the polymer is a methacrylic polymer.6. The compression-molded preparation according to claim 5 , wherein the methacrylic polymer is one kind or two or more kinds selected from the group consisting of a methyl ...

Подробнее
04-01-2018 дата публикации

ORAL DISINTEGRATING TABLET

Номер: US20180000730A1
Принадлежит:

A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process. 1. An oral disintegrating tablet having 150-740 mg comprising20-80 mg angiotensin II receptor antagonist telmisartan20-80 mg basic excipient selected from the group consisting of alkali metal hydroxides, basic amino acids and meglumine20-350 mg filler selected from the group consisting of cellulose, dibasic calcium phosphate anhydrous, erythritol, mannitol, microcrystalline cellulose, corn starch, and pregelatinized starch,20-150 mg coating agent of the first granulate selected from corn starch, pregelatinized starch, lactose, D-mannitol, erythritol or microcrystalline cellulose5-50 mg disintegrant selected from the group consisting of sodium starch glycolate, crospovidone, corn starch and pregelatinized starch2-20 mg surfactant/emulsifier poloxamer 1880.5-10 mg sweetener0.12-1.2 mg flow control agent light anhydrous silicic acid0-0.01 mg lubricant0-0.01 mg dye or pigmentwhereinthe basic excipient is meglumine;the filler is selected from the group consisting of cellulose, dibasic calcium phosphate anhydrous, erythritol, mannitol, microcrystalline cellulose corn starch and pregelatinized starch;the disintegrant is selected from the group consisting of sodium starch glycolate, crospovidone (cross-linked polyvinylpyrrolidone), corn starch and pregelatinized starch;the coating agent of the first granulate is selected from corn starch or pregelatinized starch;the lubricant is magnesium stearate;the sweetener is saccharin sodium;the dye or pigment is an iron oxide.2. The tablet of claim 1 , wherein the tablet contains 20 mg claim 1 , 40 mg or 80 mg amorphous telmisartan.3. A method of treating or preventing hypertension claim 1 , chronic stable angina claim 1 , vasospastic angina claim 1 , stroke claim 1 , myocardial infarction claim 1 , congestive heart failure claim 1 , diabetes claim 1 , dyslipidemia or dementia comprising ...

Подробнее
04-01-2018 дата публикации

ACTIVE INGREDIENT CONTAINING STABILISED SOLID FORMS AND METHOD FOR THE PRODUCTION THEREOF

Номер: US20180000739A1
Принадлежит: Losan Pharma GmbH

The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate. 2. The non-effervescent solid medicinal form of claim 1 , wherein said microcrystalline cellulose comprises 10 to 20% by weight of the capsule filling.3. The non-effervescent solid medicinal form of claim 1 , wherein said medicinal form exhibits a relative equilibrium moisture claim 1 , measured at 25° C. claim 1 , of at most 10%.4. The non-effervescent solid medicinal form of claim 1 , wherein said capsule filling further includes 0.3 to 2% by weight of stearic acid.5. The non-effervescent solid medicinal form of claim 1 , wherein said capsule filling further includes 1 to 2% by weight of stearic acid.6. The non-effervescent solid medicinal form of claim 1 , wherein said capsule filling further includes 0.2 to 2% by weight of silica.7. The non-effervescent solid medicinal form of claim 1 , wherein said solid medicinal form is packaged together with an external drying agent in a tight packaging that is substantially impermeable to water.8. The non-effervescent solid medicinal form of claim 1 , wherein the moisture-sensitive active ingredient and the trimagnesium dicitrate drying agent are dry granulated together. This application is a continuation of U.S. Ser. No. 12/441,629 filed Mar. 17, 2009, now U.S. Pat. No. 9,775,807 issued Oct. 3, 2017, which, in turn, corresponds to the national phase of International Application No. PCT/EP2007/008006 filed Sep. 14, 2007 which, in turn, claims priority to European Patent Application No. 06.020008.6 filed Sep. 25, 2006, the ...

Подробнее
02-01-2020 дата публикации

MULTICOMPONENT GUMMY COMPOSITIONS WITH HARD CORE

Номер: US20200000716A1
Принадлежит: CHURCH & DWIGHT CO., INC.

The present disclosure provides oral, chewable dosage forms that are suitable for delivery of one or more active ingredients to a consumer, particularly a human individual. The dosage forms can be configured as multicomponent compositions formed of: a first component including a gummy composition; a second component that is a particulate material or is a pre-formed solid unit or plurality of pre-formed solid units; and an active ingredient. The second component can be, for example, in the form of a pharmaceutically acceptable oral dosage unit, such as a tablet, a caplet, a soft shell capsule, a hard shell capsule, a microcapsule, or a pastille. 1. A chewable , multicomponent composition for oral administration , the multicomponent composition comprising:a first component that is a hydrocolloid system comprising about 70% to about 94% w/w of one or more hydrophilic bulking agents, about 1% to about 20% w/w of one or more hydrophilic, long chain polymers, and about 5% to about 35% w/w of a water source, the first component being in the form of a gel;a second component that is in the form of a particulate material or is a pre-formed solid unit or plurality of pre-formed solid units; andan active ingredient;wherein the first component substantially surrounds the second component.2. (canceled)3. The multicomponent composition of claim 1 , further comprising a third component configured as a layer between the first component and the second component.4. The multicomponent composition of claim 3 , wherein the third component is configured as a barrier layer that substantially prevents passage of water between the first component and the second component.5. The multicomponent composition of claim 1 , wherein one or more of the following conditions is met:the active ingredient is included in the second component;the active ingredient is included in the first component;the active ingredient is in an encapsulated form;the gummy composition is elastic or viscoelastic;the ...

Подробнее
07-01-2021 дата публикации

Pharmaceutical Composition and Preparation Method Therefor and Uses Thereof

Номер: US20210000828A1
Автор: Jiaquan WU
Принадлежит: Wuxi Shuangliang Biotechnology Co Ltd

The present disclosure belongs to the field of pharmaceutical preparations, and discloses a pharmaceutical composition and a preparation method therefor and uses thereof. The pharmaceutical composition comprising EGFR inhibitor (C-005) and the pharmaceutical tablets prepared therefrom of the present disclosure are suitable for the treatment of cancer, preferably lung cancer, particularly non-small cell lung cancer.

Подробнее
02-01-2020 дата публикации

Oral Dosage Forms Of Methyl Hydrogen Fumarate And Prodrugs Thereof

Номер: US20200000758A1
Принадлежит: Arbor Pharmaceuticals LLC

Methods of treating psoriasis with sustained release compression coated tablet dosage forms comprising certain MHF prodrugs are provided.

Подробнее
04-01-2018 дата публикации

DISPERSIBLE COMPOSITIONS

Номер: US20180000810A1
Принадлежит: Janssen Pharmaceutica NV

The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population. 1. A dispersible composition comprising bedaquiline fumarate as the active ingredient and wherein the composition comprises an intra-granular and extra-granular layer in which the intra-granular layer comprises a non-soluble excipient/diluent and is characterised in that the intra-granular layer is absent a soluble excipient/diluent that is starch.2. A dispersible composition as claimed in claim 1 , wherein the intra-granular layer is absent any soluble excipient/diluent.3. A dispersible composition as claimed in claim 1 , wherein the non-soluble excipient/diluent in the intra-granular layer is microcrystalline cellulose.4. A dispersible composition comprising bedaquiline fumarate as the active ingredient and wherein the composition comprises an intra-granular and extra-granular layer in which the intra-granular layer comprises a non-soluble excipient/diluent that is microcrystalline cellulose.5. A dispersible composition as claimed in claim 3 , wherein the intra-granular layer is absent a soluble excipient/diluent.6. A dispersible composition comprising by weight based on the total weight of the composition:5 to 50% of bedaquiline fumarate;35% to 90% of a non-soluble excipient/diluent;2% to 10% of a disintegrant;0.1 to 5% of a glidant;0.01 to 5% of a wetting agent or surfactant;0 to 10% of a binder or polymer;0 to 5% of a lubricant; andsolvent (qs).7. A dispersible composition comprising by weight based on the total weight of the composition:5 to 50% of active ingredient;20% to 90% of a non-soluble excipient/diluent that is microcrystalline cellulose;2% to 10% of a disintegrant;0.1 to 5% of a glidant;0.01 to 5% of a wetting agent or surfactant;0 to 10% ...

Подробнее
04-01-2018 дата публикации

COMBINATION THERAPY

Номер: US20180000826A1
Принадлежит:

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease. 154-. (canceled)55. A method for the treatment or amelioration of a condition or disease comprising:administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising: a) at least one angiotensin 1 receptor blocker (AT1R) or a pharmaceutically acceptable salt thereof, and b) at least one chemokine receptor 2 (CCR2) inhibitor or a pharmaceutically acceptable salt thereof,wherein the condition or disease is an MCP-1 mediated or a CCR2 mediated ...

Подробнее
04-01-2018 дата публикации

Osteoclast Inhibitors for Knee Conditions

Номер: US20180000848A1
Автор: Tabuteau Herriot
Принадлежит:

Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome. 1. A method of treating hyperalgesia associated with complex regional pain syndrome , comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from hyperalgesia associated with complex regional pain syndrome.2. The method of claim 1 , wherein a total of about 200 mg to about 500 mg of the neridronic acid is administered parenterally to the human being.3. The method of claim 1 , wherein a total of about 400 mg of the neridronic acid is administered parenterally to the human being.4. The method of claim 1 , wherein a total of about 100 mg to about 200 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.5. The method of claim 1 , wherein a total of about 250 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.6. The method of claim 2 , wherein the neridronic acid is administered in divided parenteral doses.7. The method of claim 6 , wherein each division of the divided parenteral doses contains about 10 mg to about 150 mg of the neridronic acid.8. The method of claim 6 , wherein each division of the divided parenteral doses contains about 62 mg to about 63 mg of the neridronic acid.9. The method of claim 1 , wherein the complex regional pain syndrome is associated with an inciting traumatic event.10. The method of claim 1 , wherein the human being has suffered from complex regional pain syndrome for at least 6 months.11. The method of claim 1 , wherein the human being has suffered from complex regional pain syndrome for about 6 months to about 12 months.12. The method of claim 1 , wherein the human being has suffered from complex regional pain syndrome for about 1 year to about 2 years.13. The method of claim 1 , ...

Подробнее
03-01-2019 дата публикации

COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE

Номер: US20190000864A1
Автор: Tabuteau Herriot
Принадлежит:

Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions. 1. A method of delivering zoledronic acid to the blood , comprising: orally administering a dosage form comprising zoledronic acid in a salt form to a human being in need of treatment with zoledronic acid , wherein the human being has fasted for at least one hour before the dosage form is orally administered and wherein the human being fasts for at least one hour after the dosage form is orally administered; with the proviso that the bioavailability of zoledronic acid resulting from orally administering the dosage form is no more than 4%; wherein the dosage form contains no less than 40 mg of the zoledronic acid in the salt form; and with the proviso that the bioavailability of zoledronic acid resulting from orally administering the dosage form is at least 1.1%.2. The method of claim 1 , with the proviso that the bioavailability of zoledronic acid resulting from orally administering the dosage form is no more than 3%.3. The method of claim 1 , wherein the dosage form contains about 50 mg to about 150 mg of the zoledronic acid in the salt form.4. The method of claim 1 , wherein the dosage form contains an amount of the zoledronic acid in the salt form that is about 50 mg claim 1 , about 100 mg claim 1 , or any amount between these values.5. The method of claim 1 , wherein a monthly dose of about 100 mg to about 600 mg of the zoledronic acid in the salt form is orally administered to the human being.6. The method of claim 5 , wherein the dosage form contains an amount of the zoledronic acid in the salt form that is about 50 mg claim 5 , about 100 mg claim 5 , or any amount between these values.7. The method of claim 1 , wherein the dosage form contains at least about 20% of the zoledronic acid in the salt form by weight.8. The method of claim 1 , wherein the zoledronic acid in the salt form has an aqueous ...

Подробнее
07-01-2021 дата публикации

Pharmaceutical compositions comprising meloxicam

Номер: US20210000956A1
Автор: Herriot Tabuteau

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Подробнее
02-01-2020 дата публикации

Formulations of an axl/mer inhibitor

Номер: US20200000812A1
Принадлежит: Incyte Corp

The present application relates to pharmaceutical formulations and dosage forms of an AXL/MER inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of AXL/MER mediated diseases such as cancer.

Подробнее
02-01-2020 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Номер: US20200000819A1
Автор: Tabuteau Herriot
Принадлежит:

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tof meloxicam of 3 hours or less. 1. A method of treating migraine comprising: selecting a human migraine patient with a history of inadequate response to prior migraine treatments , and orally administering a dosage form to the migraine patient , wherein the dosage form comprises a combination of: 1) a complex of meloxicam with a sulfobutyl ether β-cyclodextrin (SBEβCD) , 2) a bicarbonate , and 3) a rizatriptan , wherein the migraine patient experiences a reduction in photophobia as a result of orally administering the dosage form to the migraine patient.2. The method of claim 1 , wherein the dosage form contains 400 mg to 600 mg of the bicarbonate.3. The method of claim 1 , wherein the dosage form contains about 5 mg to about 50 mg of meloxicam.4. The method of claim 1 , wherein the dosage form contains about 50 mg to about 200 mg of the SBEβCD.5. The method of claim 1 , wherein the dosage form is a solid oral dosage form having a shorter Tof meloxicam in the human being than a reference dosage form that: 1) contains the same amount of meloxicam claim 1 , 2) does not contain an SBEβCD claim 1 , and 3) does not contain a ...

Подробнее
04-01-2018 дата публикации

DRUG DELIVERY SYSTEM TO INCREASE BIOAVAILABILITY

Номер: US20180000945A1
Принадлежит:

A drug delivery system is presented to increase the bioavailability of biopharmaceutic class II, III, or IV active agents. 2. The drug delivery system of claim 1 , wherein the glidant is silicon dioxide.3. The drug delivery system of further comprising:sodium lauryl sulfatepolyethylene glycol;lactose;cellulose;crospovidone;copovidone;a polyoxyethylene-polyoxypropylene copolymer;and sodium stearyl fumarate or magnesium stearate.4. The drug delivery system of wherein the compound of Formula I is present in amount from 10 to 40 percent by weight.5. The drug delivery system of claim 3 , wherein the sodium lauryl sulfate or polyethylene glycol is present in an amount from about 0.5 to about 3 percent or from about 2 to about 10 percent by weight claim 3 , respectively.6. The drug delivery system of claim 3 , wherein the polyethylene glycol is present in an amount from 2 to about 10 percent by weight.7. The drug delivery system of claim 3 , wherein the lactose is present in an amount from about 5 to about 20 percent by weight.8. The drug delivery system of claim 3 , wherein the cellulose is present in an amount from about 15 to about 60 percent by weight.9. The drug delivery system of claim 3 , wherein the crospovidone is present in an amount from about 5 to about 20 percent by weight.10. The drug delivery system of claim 3 , wherein the copovidone is present in an amount from about 0.2 to about 2 percent by weight.11. The drug delivery system of claim 3 , wherein the polyoxyethylene-polyoxypropylene copolymer is present in an amount from about 2 to about 5 percent by weight.12. The drug delivery system of claim 3 , wherein the sodium stearyl fumarate or magnesium stearate is present in an amount from about 0.5 to about 5 percent by weight.14. The composition of claim 13 , wherein the bioavailability of the compound of Formula I is greater than 20.15. The composition of claim 14 , wherein the bioavailability of the compound of Formula I is at least about 50.17. The method ...

Подробнее
02-01-2020 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Номер: US20200000919A1
Автор: Tabuteau Herriot
Принадлежит:

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tof meloxicam of 3 hours or less. 1. A method of treating migraine comprising: selecting a human migraine patient with a history of inadequate response to prior migraine treatments , and orally administering a solid dosage form to the migraine patient , wherein the solid oral dosage form comprises a combination of: 1) a complex of meloxicam with a sulfobutyl ether β-cyclodextrin (SBEβCD) , 2) a bicarbonate , and 3) a rizatriptan , wherein the human migraine patient is free of migraine pain two hours after the solid dosage form is orally administered to the human migraine patient.2. The method of claim 1 , wherein the solid oral dosage form contains 400 mg to 600 mg of the bicarbonate.3. The method of claim 1 , wherein the solid oral dosage form contains about 5 mg to about 50 mg of meloxicam.4. The method of claim 1 , wherein the solid oral dosage form contains about 50 mg to about 200 mg of the SBEβCD.5. The method of claim 1 , the solid oral dosage form having a shorter Tof meloxicam in the human being than a reference dosage form that: 1) contains the same amount of meloxicam claim 1 , 2) does not contain an SBEβCD claim 1 , ...

Подробнее
02-01-2020 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Номер: US20200000920A1
Автор: Tabuteau Herriot
Принадлежит:

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tof meloxicam of 3 hours or less. 1. A method of treating migraine comprising: selecting a human migraine patient with a history of inadequate response to prior migraine treatments , and orally administering a dosage form to the migraine patient , wherein the dosage form comprises a combination of: 1) a complex of meloxicam with a sulfobutyl ether β-cyclodextrin (SBEβCD) , 2) a bicarbonate , and 3) a rizatriptan , wherein the migraine patient experiences a reduction in nausea as a result of orally administering the dosage form to the migraine patient.2. The method of claim 1 , wherein the dosage form contains 400 mg to 600 mg of the bicarbonate.3. The method of claim 1 , wherein the dosage form contains about 5 mg to about 50 mg of meloxicam.4. The method of claim 1 , wherein the dosage form contains about 50 mg to about 200 mg of the SBEβCD.5. The method of claim 1 , wherein the dosage form is a solid oral dosage form having a shorter Tof meloxicam in the human being than a reference dosage form that: 1) contains the same amount of meloxicam claim 1 , 2) does not contain an SBEβCD claim 1 , and 3) does not contain a ...

Подробнее
02-01-2020 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Номер: US20200000921A1
Автор: Tabuteau Herriot
Принадлежит:

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tof meloxicam of 3 hours or less. 1. A method of treating migraine comprising: selecting a human migraine patient with a history of inadequate response to prior migraine treatments , and orally administering a dosage form to the migraine patient , wherein the dosage form comprises a combination of: 1) a complex of meloxicam with a sulfobutyl ether β-cyclodextrin (SBEβCD) , 2) a bicarbonate , and 3) a rizatriptan , wherein the human migraine patient is free of nausea two hours after the dosage form is orally administered to the human migraine patient.2. The method of claim 1 , wherein the dosage form contains 400 mg to 600 mg of the bicarbonate.3. The method of claim 1 , wherein the dosage form contains about 5 mg to about 50 mg of meloxicam.4. The method of claim 1 , wherein the dosage form contains about 50 mg to about 200 mg of the SBEβCD.5. The method of claim 1 , wherein the dosage form is a solid oral dosage form having a shorter Tof meloxicam in the human migraine patient than a reference dosage form that: 1) contains the same amount of meloxicam claim 1 , 2) does not contain an SBEβCD claim 1 , and 3) does not contain a ...

Подробнее
02-01-2020 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Номер: US20200000922A1
Автор: Tabuteau Herriot
Принадлежит:

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tof meloxicam of 3 hours or less. 1. A method of treating migraine comprising: selecting a human migraine patient with a history of inadequate response to prior migraine treatments , and orally administering a dosage form to the migraine patient , wherein the dosage form comprises a combination of: 1) a complex of meloxicam with a sulfobutyl ether β-cyclodextrin (SBEβCD) , 2) a bicarbonate , and 3) a rizatriptan , wherein the migraine patient experiences a reduction in phonophobia as a result of orally administering the dosage form to the migraine patient.2. The method of claim 1 , wherein the dosage form contains 400 mg to 600 mg of the bicarbonate.3. The method of claim 1 , wherein the dosage form contains about 5 mg to about 50 mg of meloxicam.4. The method of claim 1 , wherein the dosage form contains about 50 mg to about 200 mg of the SBEβCD.5. The method of claim 1 , wherein the dosage form is a solid oral dosage form having a shorter Tof meloxicam in the human being than a reference dosage form that: 1) contains the same amount of meloxicam claim 1 , 2) does not contain an SBEβCD claim 1 , and 3) does not contain a ...

Подробнее
03-01-2019 дата публикации

REDUCED FOAMING VACCINE COMPOSITIONS

Номер: US20190000978A1
Принадлежит:

The present invention relates to novel stable compressed vaccine composition comprising least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol. 1. A process for reducing the foaming of a solid vaccine composition when mixed with a liquid diluent , wherein the composition comprises at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming and an effervescent agent;wherein the process comprises adding an effective amount of die foam controlling agent which is a sugar alcohol to the solid vaccine composition, wherein the effective amount of sugar alcohol is about 15% to 40% by weight of the composition, andupon dissolution of the composition, the effervescent agent reacts and gas is formed in situ.2. The process according to claim 1 , wherein the process further comprises:compressing the solid vaccine composition to form a compressed vaccine composition.3. The process according to claim 1 , wherein the at least one anhydrous antigenic component is lyophilized or dried.4. The process according to claim 1 , wherein the stabilizer comprises one or more amino acid or salts thereof claim 1 , protein or salts thereof claim 1 , albumin claim 1 , gelatin claim 1 , or combinations thereof.5. The process according to claim 1 , wherein the at least one anhydrous antigenic component is newcastle disease virus claim 1 , infectious bronchitis virus claim 1 , fowl pox virus claim 1 , avian encephalomyelitis virus claim 1 , marek's disease virus claim 1 , trichophyton verrucosum claim 1 , avian paramyxovirus claim 1 , mycobacterium paratuberculosis claim 1 , meleagrid herpesvirus claim 1 , orf virus claim 1 , or sheep pox virus.6. The process according to claim 1 , wherein the at least one anhydrous antigenic component is newcastle disease virus or infectious bronchitis virus.7. The process according to claim 1 , wherein the ...

Подробнее
02-01-2020 дата публикации

BICYCLIC COMPOUNDS AS ATX INHIBITORS

Номер: US20200002336A1
Принадлежит: Hoffmann-La Roche Inc.

The invention provides novel compounds having the general formula (I) 3. A compound according to any one of and , wherein Ris selected from the group consisting of{'sub': '1-6', 'sup': 3', '4', '5, 'i) phenyl-C-alkyl substituted by R, Rand R,'}{'sup': 3', '4', '5, 'ii) pyridinyl substituted by R, Rand R, and'}{'sub': '1-6', 'sup': 3', '4', '5, 'iii) pyridinyl-C-alkyl substituted by R, Rand R.'}4. A compound according to any one of and , wherein Ris selected from the group consisting of{'sub': '1-6', 'sup': 3', '4', '5, 'i) phenyl-C-alkyl substituted by R, Rand R, and'}{'sup': 3', '4', '5, 'ii) pyridinyl substituted by R, Rand R.'}5. A compound according to any one of to , wherein Y is selected from the groups consisting ofi) —OC(O)—, andii) —C(O)—.6. A compound according to any one of to , wherein A is selected from the groups consisting ofi) —O—, andii) —S—.7. A compound according to any one of to , wherein A is —O—.8. A compound according to any one of to , wherein X is —N—.9. A compound according to any one of to , wherein W is —C(O)—.10. A compound according to any one of to , wherein Ris selected from the ring systems O , AO and AW.11. A compound according to any one of to , wherein Ris selected from the ring systems O and AO.12. A compound according to any one of to , wherein Ris selected from the groups consisting of{'sub': '1-6', 'i) C-alkylcarbonylamino, and'}{'sub': '1-6', 'ii) tetrahydropyranyl-C-alkoxy.'}13. A compound according to any one of to , wherein Ris selected from the groups consisting ofi) cyano,{'sub': '3-8', 'ii) C-cycloalkyl, and'}{'sub': '1-6', 'iii) halo-C-alkyl.'}14. A compound according to any one of to , wherein Ris selected from the groups consisting ofi) cyano, and{'sub': '3-8', 'ii) C-cycloalkyl.'}15. A compound according to any one of to , wherein Ris selected from the groups consisting ofi) H, andii) halogen.16. A compound according to any one of to , wherein m and n are independently selected from 1 and 2.17. A compound according ...

Подробнее
02-01-2020 дата публикации

Crystalline Form of Ribociclib Succinate

Номер: US20200002343A1
Принадлежит: Apotex Inc

The present invention provides a novel crystalline form of Ribociclib succinate, Ribociclib succinate Form APO-I, including Ribociclib succinate, benzyl alcohol and water, compositions thereof, processes for the preparation thereof, and the use of this crystalline form in the treatment of conditions associated with increased CDK4/6 kinase activity, and in particular, cancers, including certain forms of breast cancer.

Подробнее
07-01-2021 дата публикации

IMIDAZOTETRAZINE COMPOUNDS

Номер: US20210002286A1

New synthetic methods to provide access to previously unexplored functionality at the C8 position of imidazotetrazines. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 hours), a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent was derived. Promising compounds were identified that possess activity against a panel of GBM cell lines, appropriate hydrolytic and metabolic stability, and brain-to-serum ratios dramatically elevated relative to TMZ, leading to lower hematological toxicity profiles and superior activity to TMZ in a mouse model of GBM. 2. The compound of wherein Ris halo claim 1 , —(C-C)alkyl claim 1 , or —(C-C)cycloalkyl.3. The compound of wherein Ris —C(═O)—(C-C)alkyl claim 1 , —C(═O)—NH(C-C)alkyl claim 1 , or —C(═O)—N[(C-C)alkyl].6. The compound of wherein Ris a para-substituted phenyl.7. The compound of wherein the para-substituent is halo claim 6 , —CN claim 6 , —CF claim 6 , —CFCF claim 6 , or —(C-C)alkyl.8. The compound of wherein X is O claim 1 , Ris H and Ris —C(═O)—(C-C)alkyl claim 1 , —C(═O)—NH(C-C)alkyl claim 1 , or —C(═O)—N[(C-C)alkyl].9. The compound of wherein X is O and R is —C(═O)—(C-C)alkyl.10. The compound of wherein X is O claim 1 , Ris —(C-C)alkyl claim 1 , and Ris H.11. The compound of wherein Ris —(C-C)alkyl and Ris H.12. The compound of wherein Ris propargyl or a substituted phenyl.13. The compound of wherein the substituted phenyl is substituted with halo claim 12 , alkyl claim 12 , alkoxy claim 12 , phenoxy claim 12 , dialkylamine claim 12 , or combination thereof.17. The compound of wherein Ris —(C-C)alkyl and Ris H.18. The compound of wherein Ris CH claim 16 , CHCH claim 16 , NHCH claim 16 , NHCHCH claim 16 , N(CH) claim 16 , N(CHCH) claim 16 , N(CHCHCH) claim 16 , N(CHCHCHCH) claim 16 , N(CHCH) claim 16 , N[(CHCH)] claim 16 , OCH claim 16 , OCHCH claim 16 , SCH claim 16 , or SCHCH.22. The compound of wherein R ...

Подробнее
01-01-2015 дата публикации

COMBINED PHARMACEUTICAL FORMULATION CONTAINING DIACEREIN

Номер: US20150004229A1
Принадлежит:

The present invention relates to a combined pharmaceutical formulation having therapeutic anti-inflammatory, analgesic, antipyretic and osteoarthritis activities. From another perspective, the present invention relates to a new solid oral dosage form comprising a pharmaceutically effective amount of NSAID and a pharmaceutically effective amount of diacerein and the solid oral dosage form according to the present invention is preferably in the form of tablet and more preferably in the form of multi-layer tablet. 1. A solid oral multi-layer tablet in the form of a sandwich , wherein it comprises:i) a first layer containing a propionic acid derivative NSAID as the first active agent and pharmaceutically acceptable excipient or excipients;ii) a second layer containing diacerein as the second active agent and pharmaceutically acceptable excipient or excipients; andiii) a barrier layer positioned between these two layers and comprising pharmaceutically acceptable excipient or excipients.2. A solid oral multi-layer tablet in the form of a sandwich according to claim 1 , wherein the pharmaceutically acceptable excipient comprises at least one of binders claim 1 , disintegrants claim 1 , glidants claim 1 , lubricants claim 1 , plasticizers claim 1 , surfactants claim 1 , preservatives or mixtures thereof in a suitable amount.3. A solid oral multi-layer tablet in the form of a sandwich according to claim 2 , wherein the at least one of disintegrants is selected from microcrystalline cellulose claim 2 , croscarmellose sodium claim 2 , xylitol claim 2 , polyplasdone (1-ethenylpyrrolidin-2-one) claim 2 , crospovidone claim 2 , hydroxypropyl cellulose claim 2 , low-substituted hydroxypropyl cellulose (L-HPC) claim 2 , sodium starch glycolate or mixtures thereof.4. A solid oral multi-layer tablet in the form of a sandwich according to claim 3 , wherein the at least one of disintegrants is microcrystalline cellulose or croscarmellose sodium.5. A solid oral multi-layer tablet in the ...

Подробнее
01-01-2015 дата публикации

Tris(hydroxymethyl)Aminomethane Salts of a Small-Molecule GLP1R Agonist and Pharmaceutical Compositions and Uses Thereof

Номер: US20150005339A1
Принадлежит: Trans Tech Pharma Inc

The invention provides tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides solid compositions comprising tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides uses of tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist, e.g., for treating type 1 diabetes, type 2 diabetes, or obesity.

Подробнее
20-01-2022 дата публикации

OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS

Номер: US20220016034A1
Принадлежит:

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations. 1. A tablet comprisingabout 75 mg of 5-({[(2S)-2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid,silicified microcrystalline cellulose,colloidal silicon dioxide,crospovidone, andmannitol.2. The tablet of claim 1 , wherein said tablet comprises about 60-80% by weight of silicified microcrystalline cellulose claim 1 , about 0.55-0.95% by weight of colloidal silicon dioxide claim 1 , crospovidone claim 1 , and about 5-15% by weight of mannitol.3. The tablet of claim 1 , wherein said tablet comprises about 60-80% by weight of silicified microcrystalline cellulose claim 1 , about 0.55-0.95% by weight of colloidal silicon dioxide claim 1 , crospovidone claim 1 , and about 10% by weight of mannitol.4. The tablet of claim 1 , comprisingabout 1-20% by weight of mannitol.5. The tablet of claim 4 , comprising about 60-80% by weight of silicified microcrystalline cellulose.6. The tablet of claim 5 , comprising about 0.45-1.0% by of weight of colloidal silicon dioxide.7. The tablet of claim 6 , comprising about 5-15% by weight of mannitol.8. The tablet of claim 7 , comprising about 0.55-0.95% by weight of colloidal silicon dioxide.9. The tablet of claim 8 , comprising a lubricant.10. The tablet of claim 9 , wherein extraction of the tablet with water or saline at 25° C. for 12 hours results in a concentration of 5-({[(2S)-2-Amino-3-(4-carbamoyl-2 claim 9 ,6-dimethyl-phenyl)-propionyl]-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid of less than or approximately 4 mg/ml.11. The tablet of claim 9 , wherein extraction of the tablet at 25° C. for 12 hours in acidic solvent results in a greater ...

Подробнее
20-01-2022 дата публикации

Formulations of t-type calcium channel modulators and methods of use thereof

Номер: US20220017465A1
Принадлежит: Praxis Precision Medicines Inc

Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

Подробнее
12-01-2017 дата публикации

EXTRUDED EXTENDED RELEASE ABUSE DETERRENT PILL

Номер: US20170007544A1

The present disclosure relates to an oral, extended release pill containing a drug which is homogenously spread throughout a matrix. The pill can be prepared using a hot melt extrusion process and a forming unit. The formed pill meets regulatory guidelines for extended release formulations and can be abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations. 2. The oral claim 1 , extended release pill of claim 1 , wherein the controlled release agent is selected from the group consisting of polyvinyl acetate claim 1 , polyvinylpyrrolidone claim 1 , ethylcellulose claim 1 , hydroxypropyl methylcellulose claim 1 , hydroxypropylcellulose claim 1 , hydroxymethylcellulose claim 1 , poly(meth)acrylic acid and derivatives claim 1 , or combinations thereof.3. The oral claim 2 , extended release pill of claim 2 , wherein the formulation contains 15 wt % to 45 wt % hydroxypropyl methylcellulose as the controlled release agent.4. The oral claim 2 , extended release pill of claim 2 , wherein the formulation contains 29 wt % to 60 wt % of a combination of polyvinyl acetate and polyvinylpyrrolidone as the controlled release agent.5. The oral claim 1 , extended release pill of claim 1 , wherein the polyethylene glycol has an average molecular weight of less than 10K Daltons.6. The oral claim 1 , extended release pill of claim 1 , wherein the pill has at least 50 wt % of particles with a particle size greater than 0.5 mm following physical or mechanical manipulation of the pill.7. The oral claim 1 , extended release pill of claim 1 , wherein the drug is present at 1 to 50 wt % of the pill.8. The oral claim 1 , extended release pill of claim 1 , wherein the pill further comprises at least one preservative or antioxidant selected from the group consisting of silica claim 1 , sodium laurel sulfate claim 1 , citric acid claim 1 , butylated hydroxytoluene (BHT) claim 1 , ascorbic acid claim 1 , ascorbyl palmitate claim 1 , butylated ...

Подробнее
12-01-2017 дата публикации

A METHOD FOR COATING PHARMACEUTICAL SUBSTRATES

Номер: US20170007545A1
Принадлежит: NovalMedical Ltd Oy

The present invention relates to the field of coating pharmaceutical substrates. In particular, the invention relates to methods of coating of pharmaceutical substances, pharmaceutical ingredients or a blend of them. The invention also provides a method of making a pharmaceutical formulation which may be processed into a pharmaceutical dosage form, which utilizes solid pharmaceutical particles and a pharmaceutical formulation obtained by the method. The methods of the invention utilize atomic layer deposition technology. The novel methods allow difficult, moisture sensitive and electrically charged pharmaceutical substrates to be easily processable. 16.-. (canceled)7. A method of making a pharmaceutical formulation , the method comprising:coating particles of a pharmaceutical substrate by atomic layer deposition to produce individual coated particles of the pharmaceutical substrate;andprocessing said coated particles into a dosage form, which utilizes solid pharmaceutical particles.8. The method of claim 7 , wherein said processing employs compression of the coated particles into the dosage form.9. The method of claim 8 , wherein said dosage form is a tablet.1013.-. (canceled)14. The method of claim 7 , wherein the coating layer comprises an inorganic or organic material or a combination thereof.15. The method of claim 14 , wherein the inorganic material comprises a metal oxide.16. The method of claim 15 , wherein said metal oxide is aluminum oxide or titanium oxide.17. The method of claim 14 , wherein said inorganic or organic material comprises a tastemaking agent.18. The method of claim 17 , wherein the taste-masking agent is a sweetener.19. The method of claim 17 , wherein the taste-masking agent is a sugar alcohol. The present application is a continuation application of U.S. Ser. No. 14/428,530, filed Mar. 17, 2016, which is the National Phase of PCT/FI2013/050896 filed Sep. 17, 2013, the entire contents of which are incorporated herein by reference.The ...

Подробнее
12-01-2017 дата публикации

3,5,3'-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF

Номер: US20170007563A1
Принадлежит: BRACCO S.P.A.

The invention regards the use of triiodothyronine sulfate, commonly named TS, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T), as such or in association with thyroxine (T), and pharmaceutical formulations for oral administration thereof. 1. A daily dosage thyroid hormone composition comprising TS as the active principle , in a quantity ranging from 1 to 1000 μg;at least one diluent selected from the group consisting of: microcrystalline cellulose, calcium carbonate, magnesium carbonate, and mixtures thereof;at least one glidant selected from the group consisting of: glycerol dibenhate and talc;at least one lubricant selected from the group consisting of: magnesium stearate, zinc stearate, and colloidal silica; andat least one disintegrant selected from the group consisting of: croscarmellose or salts thereof and crosovidone or salts thereof.2. The daily dosage of wherein TS is in a quantity from 2.5 to 500 μg.3. The daily dosage of comprising TS in a range from 5-250 μg.4. The daily dosage of further comprising from 5-800 μg T4 (thyroxine).58.-. (canceled)9. The daily dosage of wherein the disintegrant is croscarmellose or salts thereof.10. (canceled)11. (canceled)12. The daily dosage of wherein the glidant is glycerol dibehenate.13. The daily dosage of in the form of a tablet.14. (canceled)15. The daily dosage of wherein the tablet is a 80-150 mg tablet.1621.-. (canceled)22. (canceled)23. A therapeutic or prophylactic treatment method for a hypothyroid condition due to total thyroid hormone depletion before I radiotherapy comprising administering the daily dosage according to to a thyroidectomised patient up to 5 days before radioactive isotope administration.24. The therapeutic treatment method of wherein said hypothyroid condition is selected from the group consisting of: asthenia claim 23 , fatigue claim 23 , skin dryness claim 23 , somnolence claim 23 , speech fluency impairment ...

Подробнее
12-01-2017 дата публикации

Process for the preparation of a solid, orally administrable pharmaceutical composition

Номер: US20170007612A1
Автор: Klaus Benke
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.

Подробнее
14-01-2016 дата публикации

Formulations of mazindol

Номер: US20160008285A1
Принадлежит: Supernus Pharmaceuticals Inc

Formulations of mazindol having superior stability and methods of administering same are provided. The formulations may be immediate, enhanced, or otherwise delayed release formulations of mazindol.

Подробнее
14-01-2016 дата публикации

BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES

Номер: US20160008312A1
Принадлежит:

A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. 1. A modified release benzonatate solid oral composition comprising (a) a homogenous solid dispersion comprising (i) benzonatate adsorbed onto one or more of a silica , silicon dioxide or silicate to form a benzonatate adsorbate and (ii) at least one pharmaceutically acceptable modified release pH-independent , hydrophilic or hydrophobic matrix-forming substance in an amount effective to provide a modified release profile to the benzonatate , and (b) a coating over said homogenous solid dispersion ,wherein there is substantially no benzonatate release from the composition in the buccal cavity, and{'sub': inf', 'max', 'max, 'wherein the composition provides a pharmacokinetic profile for benzonatate, based on an equivalent of about a 300 mg dose of benzonatate administered at 12 hour intervals in a 24 hour period, of one or more of: a geometric mean maximum plasma concentration which has an area under the curve (AUC)of about 110 ng-h/mL to about 170 ng-h/mL, a Cof about 15 ng/mL to about 25 ng/mL and/or a Tof about 12 hours to 20 hours.'}2. The modified release benzonatate composition according to claim 1 , wherein the composition provides a pharmacokinetic profile for benzonatate claim 1 , based on an equivalent of about a 300 mg dose of benzonatate administered at 12 hour intervals in a 24 hour period claim 1 , comprising one or more of: a geometric mean Cof about 30 ng/mL and/or a geometric mean AUCof about 150 ng-h/mL.3. The modified release ...

Подробнее
14-01-2016 дата публикации

Stable Pharmaceutical Package Comprising Azilsartan Medoxomil

Номер: US20160008328A1
Принадлежит: CADILA HEALTHCARE LIMITED

The present invention relates to pharmaceutical package comprising a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof, and a desiccant. Also, relates to a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof and a pH modifier, wherein pH modifier provides a pH range of about 5.5 to about 6.5 when dissolved or suspended in water at a concentration of 1% at 25° C. The invention also relates to processes for the preparation of such pharmaceutical preparation and use thereof for prophylaxis or treatment of circulatory diseases. 1. A pharmaceutical package comprising a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof , and a desiccant.2. The pharmaceutical package as claimed in claim 1 , the pharmaceutical preparation comprising azilsartan medoxomil and salts thereof claim 1 , a pH modifier claim 1 , and a desiccant claim 1 , wherein pH modifier provides a pH range of about 5.5 to about 6.5 when dissolved or suspended in water at a concentration of 1% at 25° C.3. The pharmaceutical package as claimed in claim 1 , the pharmaceutical preparation comprising azilsartan medoxomil and salts thereof claim 1 , pH modifier and a desiccant claim 1 , wherein the composition is free of odor produced by hydrolysis of (5-methyl-2-oxo-1 claim 1 ,3-dioxol-4-yl)methyl group (i.e. claim 1 , a medoxomil group) in azilsartan.4. The pharmaceutical package as claimed in claim 1 , the pharmaceutical preparation comprising azilsartan medoxomil and salts thereof claim 1 , pH modifier and a desiccant claim 1 , wherein the said pharmaceutical preparation retains at least 80% of the potency of azilsartan medoxomil and salts thereof in the pharmaceutical composition after storage at 40° C. and 75% relative humidity for three months.5. The pharmaceutical package as claimed in claim 1 , the pharmaceutical preparation comprising azilsartan medoxomil and salts thereof claim 1 , pH modifier and a desiccant claim 1 , wherein ...

Подробнее
14-01-2016 дата публикации

PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM

Номер: US20160008375A1
Принадлежит:

The present invention relates to a multilayer tablet formulation comprising a combination of quetiapine or a pharmaceutically acceptable salt thereof and escitalopram or a pharmaceutically acceptable salt thereof. 1. A multilayer tablet formulation for oral administration , comprising quetiapine or a pharmaceutically acceptable salt thereof , escitalopram or a pharmaceutically acceptable salt thereof , and one or more excipient.2. The tablet formulation according to claim 1 , comprising a layer comprising quetiapine claim 1 , a layer comprising escitalopram claim 1 , and an inert layer separating these two layers from each other.3. The tablet formulation according to claim 1 , wherein the excipient is a disintegrant claim 1 , and the ratio of the amount of the disintegrant present in the layer comprising quetiapine to the amount of the disintegrant present in the layer comprising escitalopram is between 1/1 and 25/1.4. The tablet formulation according to claim 3 , wherein the ratio of the amount of the disintegrant present in the layer comprising quetiapine to the amount of the disintegrant present in the layer comprising escitalopram is between 2/1 and 20/1.5. The tablet formulation according to claim 3 , wherein the disintegrant is selected from the group consisting of alginic acid and alginates claim 3 , ion-exchange resins claim 3 , magnesium aluminum silicate claim 3 , sodium dodecyl sulfate claim 3 , sodium carboxymethyl cellulose claim 3 , croscarmellose sodium claim 3 , cross linked polyvinylpyrrolidone claim 3 , carboxymethylcellulose calcium claim 3 , docusate sodium claim 3 , guar gum claim 3 , corn starch claim 3 , polacrilin potassium claim 3 , poloxamer claim 3 , povidone claim 3 , sodium alginate claim 3 , sodium glycine carbonate claim 3 , sodium lauryl sulfate claim 3 , sodium starch glycolate claim 3 , and mixtures thereof.6. The tablet formulation according to claim 1 , wherein the ratio of the inert layer thickness to the total tablet thickness ...

Подробнее
14-01-2021 дата публикации

COMPOSITIONS FOR STABILIZING AND DELIVERING PROTEINS

Номер: US20210007990A1
Принадлежит:

Compositions for stabilizing and delivering proteins and/or other bioactive agents are disclosed. The bioactive agents are embedded or encapsulated in a crystalline matrix. Typically the bioactive agents are in the form of micro- or nanoparticles. The crystalline matrix confers enhanced stability to the agents embedded therein relative to other microparticulate or nanoparticulate bioactive agents. The carriers are especially useful for stabilizing bioactive macromolecules, such as proteins. 123.-. (canceled)24. A method of making a composition comprising a semi-crystalline matrix comprising (i) microparticles , nanoparticles , or a combination thereof , comprising a protein or peptide and at least one biocompatible polymer , wherein the microparticles , nanoparticles , or a combination thereof is entrapped in the matrix , and (ii) at least one semi-crystalline water soluble polymer , wherein the total amount of the semi-crystalline water soluble polymer in the matrix is at least 65% by weight of the total mass of the matrix , wherein the matrix is characterized by a melting point of at least 40° C. ,the method comprising:(a) dissolving the semi-crystalline water soluble polymer in an effective amount of a solvent,(b) dissolving or dispersing microparticles, nanoparticles, or a combination thereof, comprising the protein or peptide and at least one biocompatible polymer, in the effective amount of the solvent of step (a), wherein the semi-crystalline water soluble polymer, the microparticles, nanoparticles, or a combination thereof, and the solvent form a mixture having a continuous phase and wherein the solvent is the continuous phase, and 1) introducing the product of step (b) into an effective amount of a non-solvent,', '2) spray drying the product of step (b),', '3) film casting the product of step (b),', '4) pan coating the product of step (b) in a fluidized bed reactor, or', '5) lyophilizing the product of step (b)., '(c) performing at least one of the ...

Подробнее